Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Prusogliptin in Healthy Subjects
NCT05150626Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of prusogliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Peak Plasma Concentration at Day 9, Area Under the Plasma Concentration versus Time Curve from Time Zero to Last Measurable Concentration at Day 9 and 1 more. Started May 2022; status: completed.
02
Drugs
prusogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05150626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05150626.